Abstract
Binding of ( 3H)-ouabain and ouabain-induced inhibition of the sodium pump and of the (Na + + K +)-ATPase have been characterized in cultured cardiac muscle and non muscle cells, as well as in cardiac cell membranes—all obtained from chick embryos. 1. In both cell types, ouabain binds to a single type of binding sites in a temperature-dependent manner. The association rate but not the dissociation rate, is lowered by K +; specific binding is lost after heat-denaturation of the cells. Binding parameters (association and dissociation rate constants, activation energies for association and dissociation) are similar in muscle and non muscle cells. The dissociation constant of specific ouabain binding is 1.5 × 10 −7 M in cardiac muscle cells, and 1.9 × 10 −7 M in cardiac non muscle cells, the binding capacity being 2.6 and 2.1 pmoles/mg protein respectively. 2. Specific binding of ouabain to the cells is coupled to inhibition of the sodium pump, as can be seen from ouabain-induced inhibition of active ( 86Rb + + K +)-uptake, decrease in cellular K +, and increase in cellular Na + (EC 50 = 10 −7−10 −6 M). 3. The data obtained with cardiac cells are in good agreement with results found for ouabain binding (dissociation constant 4.3 × 10 −7 M) and (Na + + K +)-ATPase inhibition (EC 50 = 1.4 × 10 −6 M) in cardiac cell membranes prepared from the same tissue. 4. Due to the experimental evidence it is concluded that the binding site for ouabain is identical with the cardiac glycoside receptor of these cells. 5. In cardiac non muscle cells, binding of ouabain to its receptor is strictly coupled to inhibition of active K +-transport in a stoichiometric manner. In cardiac muscle cells, however, active K +-transport is inhibited by less than 10% when up to 40% of cardiac glycoside receptors have bound ouabain. It is assumed that this non-stoichiometric coupling of receptor occupancy and sodium pump inhibition in cardiac muscle cells may prevent substantial changes of Na +- and K +-contents in the heart in the presence of therapeutic levels of cardiac glycosides.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.